Westin, S. N., Sill, M. W., Coleman, R. L., Waggoner, S., Moore, K. N., Mathews, C. A., . . . Aghajanian, C. (2019). Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study. Gynecol Oncol.
Citação norma ChicagoWestin, Shannon N., et al. "Safety Lead-In of the MEK Inhibitor Trametinib in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent Endometrial Cancer: An NRG Oncology/GOG Study." Gynecol Oncol 2019.
MLA citiranjeWestin, Shannon N., et al. "Safety Lead-In of the MEK Inhibitor Trametinib in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent Endometrial Cancer: An NRG Oncology/GOG Study." Gynecol Oncol 2019.